Memantine Dosing Regimen Starting at 5 mg
Start memantine at 5 mg once daily and titrate upward in 5 mg weekly increments to a target dose of 20 mg/day (10 mg twice daily) for moderate to severe Alzheimer's disease. 1
Standard Titration Schedule
The FDA-approved dosing regimen follows a structured 4-week titration:
- Week 1: 5 mg once daily
- Week 2: 10 mg/day (5 mg twice daily)
- Week 3: 15 mg/day (5 mg morning, 10 mg evening as separate doses)
- Week 4 onward: 20 mg/day (10 mg twice daily) - this is the therapeutic target dose 1
The minimum interval between dose increases must be one week to allow for tolerance and minimize adverse effects 1.
Key Administration Details
- Memantine can be taken with or without food 1
- If a single dose is missed, do not double the next dose - simply resume the regular schedule 1
- If multiple days are missed, restart at lower doses and retitrate following the original schedule 1
- The 20 mg/day dose is what demonstrated efficacy in controlled trials 1
Special Population Adjustments
Severe Renal Impairment
For patients with creatinine clearance 5-29 mL/min, the target dose is reduced to 5 mg twice daily (10 mg/day total) rather than the standard 20 mg/day 1. This is critical as memantine is renally eliminated and accumulation occurs with impaired kidney function.
Severe Hepatic Impairment
Administer with caution but no specific dose adjustment is mandated 1.
Clinical Context
Memantine is FDA-approved specifically for moderate to severe Alzheimer's disease 1. The 2020 Canadian Consensus Conference supports its use in AD, Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), and vascular dementia (VD) 2. However, evidence shows only statistically significant but not clinically important improvements in cognition, with more meaningful benefits seen in global assessment and quality of life measures 3.
Common Pitfalls to Avoid
- Do not rush titration: The weekly interval exists to minimize adverse effects like confusion, dizziness, and falls 2, 1
- Do not use 5 mg as a maintenance dose in patients with normal renal function - this is subtherapeutic 1
- Do not mix the oral solution with other liquids if using liquid formulation 1
- Discontinue if prescribed for non-approved indications like frontotemporal dementia or mild cognitive impairment 2
Safety Monitoring
Withdrawal rates due to adverse events in trials were 7-12%, with the most common issues being confusion, dizziness, falls, nausea, and agitation 3, 1. These are generally manageable with slower titration if needed.